Gas Utilities Stocks Show Relative Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Source: NASDAQ.COM
- Market Performance: Gas utilities stocks collectively rose by approximately 1.2%, indicating relative strength in the market and reflecting a gradual recovery in investor confidence towards the sector.
- Leading Companies: Stabilis Solutions saw its stock price increase by about 6.4%, making it the top performer of the day, suggesting its growing competitiveness and investment appeal in the market.
- Other Company Dynamics: Chesapeake Utilities' stock rose by approximately 1.8%, further solidifying its market position in the gas utilities sector, which may attract more investor attention.
- Industry Trends: With hospital and medical practitioners also showing strong performance, the rise in gas utilities could signal a broader economic recovery, prompting investors to monitor the implications of this trend on future market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALHC
Wall Street analysts forecast ALHC stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 21.660
Low
18.00
Averages
21.81
High
30.00
Current: 21.660
Low
18.00
Averages
21.81
High
30.00
About ALHC
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alignment Healthcare Executive Sells Shares
- Executive Share Sale: Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare, sold 25,000 shares on June 18, 2026, for $550,000, representing 2.12% of his direct holdings, indicating a measured reduction consistent with his historical trading patterns.
- Trading Plan Context: The transaction was executed under a Rule 10b5-1 plan adopted on March 4, 2026, suggesting routine portfolio management rather than discretionary selling, with Konowiecki retaining 1,153,816 shares post-sale, maintaining significant exposure to the company's future performance.
- Company Financial Performance: In Q1 2026, Alignment Healthcare reported revenue of $1.24 billion, a 33.3% year-over-year increase, with membership rising 30.9% to approximately 284,800 members, and net income turning positive at $11.4 million, showcasing strong performance in the Medicare Advantage market.
- Future Growth Outlook: Management raised expectations for membership, revenue, and adjusted EBITDA, with CEO John Kao highlighting improvements in sales, clinical operations, and cost management, indicating Alignment Healthcare's potential for sustainable growth in a competitive landscape.
See More
Konowiecki Sells 25,000 Shares of Alignment Healthcare
- Transaction Overview: Joseph S. Konowiecki sold 25,000 shares on June 18, 2026, for $550,000 at $22.00 per share, representing 2.1% of his direct holdings, leaving him with 1,153,816 shares, which reflects his ongoing confidence in Alignment Healthcare's future performance.
- Background Analysis: The sale was executed under a prearranged Rule 10b5-1 trading plan adopted in March, which mitigates the risk of market misinterpretation regarding the timing of the transaction, indicating a cautious approach to managing his holdings while ensuring long-term investment in the company.
- Company Performance Highlights: Alignment Healthcare achieved a 33.3% year-over-year revenue increase in Q1 2026, reaching $1.24 billion, with membership growing by 30.9% to approximately 284,800 members, showcasing strong performance and enhanced profitability in the Medicare Advantage market.
- Management Confidence Boost: The management raised the midpoint of its full-year guidance for membership, revenue, and adjusted EBITDA, indicating that Alignment Healthcare can sustain profitable growth even as many healthcare companies face challenges, thus reinforcing investor confidence in its strategic direction.
See More
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
John E. Kao Sells 298,000 Shares Indirectly
- Sale Overview: On May 11, 2026, John E. Kao, CEO of Alignment Healthcare, indirectly sold 298,000 shares of common stock through the JEK Trust for approximately $5.03 million, representing 8.30% of his total holdings at the time.
- Holding Status: Post-transaction, Kao retains 1,784,868 shares directly and 1,508,641 shares indirectly, indicating his continued confidence in the company's long-term trajectory despite recent reductions in his holdings.
- Market Environment Analysis: The Medicare Advantage sector is under pressure from elevated medical cost ratios, with Alignment's key challenge being to demonstrate cost discipline while scaling, particularly in risk pricing and care utilization management.
- Long-Term Outlook: Despite facing policy risks and market challenges, the growing senior population and increasing penetration of Medicare Advantage suggest a significant market opportunity for Alignment Healthcare, with Kao's combined position exceeding three million shares reflecting his optimism about the company's future.
See More
Alignment Healthcare CEO Sells 298,000 Shares for $5.03 Million
- Transaction Overview: On May 11, 2026, Alignment Healthcare CEO John E. Kao sold 298,000 shares of common stock for approximately $5.03 million, which is significantly above his average sell size of 165,200 shares over the past two years, indicating a notable shift in his ownership structure.
- Ownership Structure Change: This transaction reduced Kao's indirect holdings by 16.49%, leaving him with 1,508,641 shares in the JEK Trust while maintaining a direct holding of 1,784,868 shares, reflecting his continued confidence in the company's long-term trajectory.
- Market Reaction: The weighted average sale price of $16.89 per share was slightly below the market close of $17.16 on May 11, 2026, but above the current price of $15.73 as of May 17, 2026, suggesting that Kao executed the sale under relatively favorable market conditions.
- Industry Context: Amid ongoing pressures in the Medicare Advantage sector, Alignment Healthcare must demonstrate cost discipline to sustain growth, although the increasing senior population and Medicare penetration provide a long-term market opportunity.
See More
Alignment Healthcare Joins S&P SmallCap 600 Index
- Stock Surge: Alignment Healthcare's shares jumped 7.8% in the afternoon session, reflecting market optimism regarding its inclusion in the S&P SmallCap 600 index, which is expected to attract more investor interest.
- Index Composition Change: According to the announcement, Alignment Healthcare will replace Sun Country Airlines Holdings before trading begins on May 14, meaning its stock will be forcibly purchased by index funds and ETFs, thereby increasing demand and pushing the stock price higher.
- Market Volatility: Over the past year, Alignment Healthcare's stock has experienced 23 moves greater than 5%, indicating that while today's increase is seen as significant, the market's perception of the company's fundamentals remains unchanged.
- Long-term Performance: Since the beginning of the year, Alignment Healthcare's stock has declined by 8.8%, currently trading at $18.45, which is 22.5% below its 52-week high of $23.81, showing that investors who bought $1,000 worth of shares five years ago would now see a return of only $865.20, indicating a loss on their initial investment.
See More
Alignment Healthcare Executive Sells Shares
- Executive Share Sale: Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare, sold 25,000 shares on June 18, 2026, for $550,000, representing 2.12% of his direct holdings, indicating a measured reduction consistent with his historical trading patterns.
- Trading Plan Context: The transaction was executed under a Rule 10b5-1 plan adopted on March 4, 2026, suggesting routine portfolio management rather than discretionary selling, with Konowiecki retaining 1,153,816 shares post-sale, maintaining significant exposure to the company's future performance.
- Company Financial Performance: In Q1 2026, Alignment Healthcare reported revenue of $1.24 billion, a 33.3% year-over-year increase, with membership rising 30.9% to approximately 284,800 members, and net income turning positive at $11.4 million, showcasing strong performance in the Medicare Advantage market.
- Future Growth Outlook: Management raised expectations for membership, revenue, and adjusted EBITDA, with CEO John Kao highlighting improvements in sales, clinical operations, and cost management, indicating Alignment Healthcare's potential for sustainable growth in a competitive landscape.
See More
Konowiecki Sells 25,000 Shares of Alignment Healthcare
- Transaction Overview: Joseph S. Konowiecki sold 25,000 shares on June 18, 2026, for $550,000 at $22.00 per share, representing 2.1% of his direct holdings, leaving him with 1,153,816 shares, which reflects his ongoing confidence in Alignment Healthcare's future performance.
- Background Analysis: The sale was executed under a prearranged Rule 10b5-1 trading plan adopted in March, which mitigates the risk of market misinterpretation regarding the timing of the transaction, indicating a cautious approach to managing his holdings while ensuring long-term investment in the company.
- Company Performance Highlights: Alignment Healthcare achieved a 33.3% year-over-year revenue increase in Q1 2026, reaching $1.24 billion, with membership growing by 30.9% to approximately 284,800 members, showcasing strong performance and enhanced profitability in the Medicare Advantage market.
- Management Confidence Boost: The management raised the midpoint of its full-year guidance for membership, revenue, and adjusted EBITDA, indicating that Alignment Healthcare can sustain profitable growth even as many healthcare companies face challenges, thus reinforcing investor confidence in its strategic direction.
See More
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
John E. Kao Sells 298,000 Shares Indirectly
- Sale Overview: On May 11, 2026, John E. Kao, CEO of Alignment Healthcare, indirectly sold 298,000 shares of common stock through the JEK Trust for approximately $5.03 million, representing 8.30% of his total holdings at the time.
- Holding Status: Post-transaction, Kao retains 1,784,868 shares directly and 1,508,641 shares indirectly, indicating his continued confidence in the company's long-term trajectory despite recent reductions in his holdings.
- Market Environment Analysis: The Medicare Advantage sector is under pressure from elevated medical cost ratios, with Alignment's key challenge being to demonstrate cost discipline while scaling, particularly in risk pricing and care utilization management.
- Long-Term Outlook: Despite facing policy risks and market challenges, the growing senior population and increasing penetration of Medicare Advantage suggest a significant market opportunity for Alignment Healthcare, with Kao's combined position exceeding three million shares reflecting his optimism about the company's future.
See More
Alignment Healthcare CEO Sells 298,000 Shares for $5.03 Million
- Transaction Overview: On May 11, 2026, Alignment Healthcare CEO John E. Kao sold 298,000 shares of common stock for approximately $5.03 million, which is significantly above his average sell size of 165,200 shares over the past two years, indicating a notable shift in his ownership structure.
- Ownership Structure Change: This transaction reduced Kao's indirect holdings by 16.49%, leaving him with 1,508,641 shares in the JEK Trust while maintaining a direct holding of 1,784,868 shares, reflecting his continued confidence in the company's long-term trajectory.
- Market Reaction: The weighted average sale price of $16.89 per share was slightly below the market close of $17.16 on May 11, 2026, but above the current price of $15.73 as of May 17, 2026, suggesting that Kao executed the sale under relatively favorable market conditions.
- Industry Context: Amid ongoing pressures in the Medicare Advantage sector, Alignment Healthcare must demonstrate cost discipline to sustain growth, although the increasing senior population and Medicare penetration provide a long-term market opportunity.
See More
Alignment Healthcare Joins S&P SmallCap 600 Index
- Stock Surge: Alignment Healthcare's shares jumped 7.8% in the afternoon session, reflecting market optimism regarding its inclusion in the S&P SmallCap 600 index, which is expected to attract more investor interest.
- Index Composition Change: According to the announcement, Alignment Healthcare will replace Sun Country Airlines Holdings before trading begins on May 14, meaning its stock will be forcibly purchased by index funds and ETFs, thereby increasing demand and pushing the stock price higher.
- Market Volatility: Over the past year, Alignment Healthcare's stock has experienced 23 moves greater than 5%, indicating that while today's increase is seen as significant, the market's perception of the company's fundamentals remains unchanged.
- Long-term Performance: Since the beginning of the year, Alignment Healthcare's stock has declined by 8.8%, currently trading at $18.45, which is 22.5% below its 52-week high of $23.81, showing that investors who bought $1,000 worth of shares five years ago would now see a return of only $865.20, indicating a loss on their initial investment.
See More
